Tiny samples could yield big predictive markers for pancreatic cancer

March 10, 2009,

A handful of proteins, detected in incredibly tiny amounts, may one day help doctors distinguish between a harmless lesion in the pancreas and a potentially deadly one, say researchers at Fox Chase Cancer Center.

The researchers believe that these , if confirmed in subsequent studies, could represent reliable indicators of or precancerous pancreatic lesions, which would allow for earlier, perhaps more successful, treatment. Their findings appear in the March issue of the journal Pancreas, available online now.

"New technologies have become very good at identifying when they appear, but we know very little about how to categorize these cysts," says the study's senior author Anthony Yeung, Ph.D., molecular biologist and member of Fox Chase's faculty. "We can detect, in as little as 40 of cyst fluids a group of proteins that might collectively be used as indicators of a potentially cancerous cyst."

The difficulty of detecting pancreatic cancer early is one of the reasons that the disease remains one of the deadliest forms of cancer. In some cases, pancreatic cancer develops within small pancreatic cysts that are originally benign, but become cancerous over time. As high-resolution imaging techniques, such as (), are used more often in clinical medicine, doctors are finding many more small, fluid-filled cystic lesions of the pancreas.

"Many of these cysts are completely benign and have little or no risk of becoming cancerous. However, a subset of pancreatic cysts carry a real risk of becoming malignant over time," says co-author Jeffrey Tokar, M.D., Fox Chase gastroenterologist. "Many patients with pancreatic cysts are referred to us for endoscopic of fluid within the cyst, which is then sent to the laboratory and a variety of tests are commonly performed. However, while these tests can be useful, it often remains impossible to tell a patient their absolute risk of progression to cancer."

According to Tokar, there are currently two main options for doctors once they find a pancreatic cyst, and neither is ideal. One option is to advise the patient to have major surgery to remove the portion of the pancreas that contains the cyst, in hopes of eliminating the chance that it will develop into cancer. Unfortunately, with this approach, some patients will be subjected to the risks of surgery for a cyst that was never going to cause them any problems. The other option is to take a "watch-and-wait" approach, which can become costly, expose patients to additional radiation (i.e., if computerized tomography, or CT scans, are used), and may not always detect cancers within cysts at its earliest stages. "What we need are methods to identify benign cysts that do not have significant cancer risk, so that we can concentrate on the cysts that have the greatest risk of malignancy," Tokar says.

Using an endoscopic ultrasound-guided technique, Tokar and his colleagues collected fluid from the cysts of 20 research participants with a small needle. Yeung and his laboratory team then assayed the fluid to determine the number and type of proteins it contained. Identifying the proteins took more than eight months of continuous time with a mass spectrometer, an instrument that can determine the makeup of - and thereby identify - individual molecules. Among the proteins they found were members of three families of proteins previously proposed to be biomarkers for pancreatic cancer, called mucins, CEACAMs, and S100s.

"From these samples we've identified a panel of these proteins that could all be considered harbingers of cancer in some way," Yeung says. "Now that we know what we are looking for, we can use even more powerful spectrometry techniques to find this pattern of proteins fast enough that it could be used as part of a clinical service."

The researchers are looking to expand their study and to follow patients over a longer period of time to see how well this biomarker profile predicts the likelihood that a pancreatic lesion already contains or may develop into pancreatic cancer, but they will need to recruit more patients. Fortunately, it helps that they can do more with less, as their technique can find biomarkers amid very small amounts of fluid obtained from small pancreatic lesions that are less than one centimeter (0.39 inches) in size.

"We are in great need for powerful tests, such as the ones that Dr. Yeung performs, which require only a tiny volume of fluid but can provide a tremendous amount of useful information," says Tokar. "We will need to work with colleagues at multiple medical centers to continue studying this promising technique for evaluating pancreatic cyst fluid, in hopes of building enough evidence to make it a routine part of patient care."

Source: Fox Chase Cancer Center

Related Stories

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.